SEMA3C and pachyonychia congenita: Furthermore, the combination of trametinib (MEK inhibitor, downstream of KRAS) and Sema3C inhibitor can induce a synergistic effect in KRAS G12D cells, which shows Sema3C might be a potentially prospects and attractive target for PC therapy, especially in patients with G12D mutation in KRAS (22).